articleTop 1% cited

<b>CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment:</b> A Quantitative Analysis Correlated with FDG PET Findings

American Journal of Roentgenology · 2004 · Vol. 183(6) · pp. 1619–1628

Haesun Choi✉(The University of Texas MD Anderson Cancer Center)C Charnsangavej(The University of Texas MD Anderson Cancer Center)Silvana de Castro Faria(The University of Texas MD Anderson Cancer Center)Eric P. Tamm(The University of Texas MD Anderson Cancer Center)Robert S. Benjamin(The University of Texas MD Anderson Cancer Center)Marcella M. Johnson(The University of Texas MD Anderson Cancer Center)Homer A. Macapinlac(The University of Texas MD Anderson Cancer Center)Donald A. Podoloff(The University of Texas MD Anderson Cancer Center)

View via DOI Publisher page

Abstract

FDG PET is sensitive and specific for evaluating tumor response but cannot be used in patients whose baseline FDG PET results are negative for tumors. Although subjective evaluation was a better indicator of treatment response than was tumor density alone, the tumor density measurement is a good indicator and provides a reliable quantitative means of monitoring the tumor. RECIST, using only tumor size, was unreliable for monitoring GISTs during the early stage of imatinib mesylate treatment.

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Soft tissue tumor case studiesMedicineImatinib mesylateResponse Evaluation Criteria in Solid TumorsStromal tumorStandardized uptake valueNuclear medicineProgressive diseaseInternal medicineStromal cellImatinib

MeSH terms

Imatinib MesylateAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesFemaleHumansMaleMiddle AgedPiperazinesPyrimidinesRadionuclide ImagingRetrospective StudiesTomography, X-Ray Computed

Citations

455

FWCI

12.00

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

References

KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors